Empagliflozin markedly improves BMI, blood sugar, BP in diabetics: SUPER GATE study Medha18 Sep 2021 3:30 AM GMTBolu, Turkey: Empagliflozin add-on treatment improved metabolic parameters, blood pressure, and anthropometric measures and did not deteriorate kidney ...
Empagliflozin significantly reduces hospitalization risk in patients of HFpEF, shows trial Dr. Kamal Kant Kohli30 Aug 2021 12:30 AM GMTFrance: SGLT-2 inhibitor, Empagliflozin significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status, reveal...
FDA approves empagliflozin for heart failure with reduced ejection fraction in adults Dr. Kamal Kant Kohli21 Aug 2021 1:45 AM GMTThe U.S. Food and Drug Administration has approved Jardiance (empagliflozin) to reduce the risk of cardiovascular mortality plus hospitalization for...
EMPEROR-Preserved confirms success of Empagliflozin in HFpEF Hina Zahid8 July 2021 4:15 AM GMTEmpagliflozin therapy with specific benefits in patients with heart failure and preserved ejection fraction (HFpEF) may finally be on its way as the...
SGLT-2 Inhibitors may Improve Endothelial Function in T2D with CVD: Study Dr Kartikeya Kohli2 July 2021 3:30 AM GMTEmpagliflozin treatment has potential to improve endothelial function and has cardiovascular benefits, finds new study.
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha2 Jun 2021 4:00 AM GMTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular ...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 10:40 AM GMTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
Empagliflozin Improves Heart Failure with rEF in Nondiabetic patients: Study MD Bureau31 Jan 2021 9:48 AM GMTIn patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to...
Lupin gets USFDA nod for Empagliflozin, Metformin Hydrochloride ER Tablets ruchika8 Jan 2021 5:49 AM GMTMumbai, Baltimore: Drugmaker, Lupin Limited, has recently announced that the company has received tentative approval for its Empagliflozin and Met...
Empagliflozin can treat and reverse heart failure in non-diabetic patients also: Study Dr. Kamal Kant Kohli16 Nov 2020 5:00 AM GMTResearchers at the Icahn School of Medicine at Mount Sinai have found in a new trial known as EMPATROPISM, that diabetes drug Empagliflozin can...
Empagliflozin plus loop diuretics significantly increase urine volume in diabetes with HF Medha10 Nov 2020 4:45 AM GMTUK: The use of SGLT2 inhibitor empagliflozin in combination with loop diuretics in patients with type 2 diabetes (T2D) and heart failure, helps in...
Empagliflozin may reduce hospitalization and death risk in heart failure: Study Dr Satabdi Saha26 Oct 2020 2:30 AM GMTAccording to a recent research, patients receiving empagliflozin therapy for heart failure, showed a lower risk of cardiovascular death or...
